Faruqi and Faruqui, LLP Logo
Share this page

Uroplasty, Inc. (UPI)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Uroplasty, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Uroplasty, Inc. (“Uroplasty” or the “Company”) (NASDAQ: UPI).

The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies.  Specifically, the investigation focuses on whether Uroplasty failed to disclose that it improperly recognized revenues and that it made improper payments of commission sales.

On June 14, 2013, the Company announced that it would delay filing its Annual Report for the year ended March 31, 2013, pending a review of its internal control regarding financial reporting.  It further stated that its Chief Financial Officer would be placed on administrative leave.  Following this news, Uroplasty’s stock price dropped over 10%.

Take Action

If you invested in Uroplasty’s stock or options between July 26, 2012 and June 13, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Uroplasty’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 07/03/2013

Class Period:

  • 07/26/2012 - 06/13/2013

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.